The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action
Research output: Contribution to journal › Journal article › Research › peer-review
Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic beta- and alpha-cells. Previous studies have focused on the improvements in beta-cell function, while the inhibition of alpha-cell secretion has received less attention. The aim of this research was to quantify the glucagonostatic contribution to the glucose-lowering effect of GLP-1 infusions in patients with type 2 diabetes.
|Number of pages||6|
|Publication status||Published - 1 Jul 2010|
- Adult, Analysis of Variance, Area Under Curve, Blood Glucose, Diabetes Mellitus, Type 2, Glucagon, Glucagon-Like Peptide 1, Glucose Clamp Technique, Humans, Insulin, Male, Middle Aged, Time Factors, Treatment Outcome